Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shu-Chih Su

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The Lancet. Infectious Diseases|August 11, 2019
Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trialKathleen M Mullane, Vicki A Morrison, Luis H Camacho, et al.
Open Forum Infectious Diseases|July 16, 2020
Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic CancerMichael J Boeckh, Ann M Arvin, Kathleen M Mullane, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 30, 2008
Short telomeres are a risk factor for idiopathic pulmonary fibrosisJonathan K Alder, Julian J-L Chen, Lisa Lancaster, et al.
The Pediatric Infectious Disease Journal|July 9, 2020
A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy InfantsHeather L Platt, David Greenberg, Bruce Tapiero, et al.
The Journal of Infectious Diseases|August 3, 2013
Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccineMyron J Levin, Kenneth E Schmader, John W Gnann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 2012
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 yearsKenneth E Schmader, Myron J Levin, John W Gnann, et al.
The Lancet. Oncology|July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyCaroline Robert, Antoni Ribas, Jacob Schachter, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 23, 2014
Long-term persistence of zoster vaccine efficacyVicki A Morrison, Gary R Johnson, Kenneth E Schmader, et al.
Lancet (London, England)|June 2, 2018
Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trialDrew J Winston, Kathleen M Mullane, Oliver A Cornely, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Lancet. Infectious Diseases|August 11, 2019
Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trialKathleen M Mullane, Vicki A Morrison, Luis H Camacho, et al.
Open Forum Infectious Diseases|July 16, 2020
Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic CancerMichael J Boeckh, Ann M Arvin, Kathleen M Mullane, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 30, 2008
Short telomeres are a risk factor for idiopathic pulmonary fibrosisJonathan K Alder, Julian J-L Chen, Lisa Lancaster, et al.
The Pediatric Infectious Disease Journal|July 9, 2020
A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy InfantsHeather L Platt, David Greenberg, Bruce Tapiero, et al.
The Journal of Infectious Diseases|August 3, 2013
Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccineMyron J Levin, Kenneth E Schmader, John W Gnann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 2012
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 yearsKenneth E Schmader, Myron J Levin, John W Gnann, et al.
The Lancet. Oncology|July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyCaroline Robert, Antoni Ribas, Jacob Schachter, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 23, 2014
Long-term persistence of zoster vaccine efficacyVicki A Morrison, Gary R Johnson, Kenneth E Schmader, et al.
Lancet (London, England)|June 2, 2018
Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trialDrew J Winston, Kathleen M Mullane, Oliver A Cornely, et al.
Pageof 2